Key result
Valve-in-valve TAVI using ACURATE neo2 achieves ~98% technical success and marked functional class improvement.
Why the study?
The ACURATE neo2 valve represents a promising solution for the challenges of ViV TAVI, but procedural, 30-day, and 1-year outcomes required evaluation.
Does valve-in-valve TAVI with the ACURATE neo2 valve provide safe and effective outcomes in patients with symptomatic bioprosthetic valve dysfunction?
Observational (n=55)
No
Does valve-in-valve TAVI with the ACURATE neo2 valve provide safe and effective outcomes in patients with symptomatic bioprosthetic valve dysfunction?
The ACURATE neo2 valve demonstrated high technical success, excellent safety, and sustained hemodynamic improvement in patients undergoing valve-in-valve TAVI for degenerated surgical bioprostheses.
Answers are grounded in this paper and cite their sources.
Supports feasibility of ACURATE neo2 valve-in-valve TAVI; hypothesis-generating pending randomized confirmation of durability.
Background/Objectives: Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is a key approach for treating degenerated surgical bioprosthetic valves. The ACURATE neo2 valve, with its advanced sealing technology and optimized coronary access, represents a promising solution for the challenges of ViV TAVI. This study evaluates the procedural and 30-day and 1-year follow-up outcomes of the ACURATE neo2 valve in ViV TAVI. Methods: This single-center, single-operator prospective study included patients with symptomatic bioprosthetic valve dysfunction, classified in New York Heart Association (NYHA) class III or IV, who underwent ViV TAVI with ACURATE neo2 at our center between July 2022 and February 2024. Outcomes were assessed using VARC-3 criteria. Results: Fifty-five patients (51% females, median (IQR) age 76 (8) years) were included. The technical success rate was 98.2%. No patients experienced in-hospital mortality, stroke, MI, bleeding, vascular complications, renal failure, or new pacemaker implantation. Three patients (5.5%) underwent elective chimney stenting for coronary protection. The postprocedural mean aortic gradient was 6.7 ± 1 mmHg, with a mean aortic valve area (AVA) of 2.0 ± 0.1 cm2. Over a median follow-up period of 1.2 years, no deaths (0%) were observed, heart failure hospitalization rate was 3.6%, and NYHA class improved to ≤II in 100% of patients. Conclusions: ACURATE neo2 demonstrated excellent technical success, sustained hemodynamic performance, and significant clinical improvement in ViV TAVI. The absence of major adverse events reinforces its safety, efficacy, and durability as a treatment for degenerated surgical bioprostheses.
No takes yet. Share an insight, caveat, or question.
Papadopoulos et al. (2025) conducted an observational in Symptomatic bioprosthetic valve dysfunction (n=55). ACURATE neo2 valve was evaluated on Technical success rate. Valve-in-valve TAVI using the ACURATE neo2 valve achieved a 98.2% technical success rate with 0% mortality and 100% improvement to functional class ≤II over a median follow-up of 1.2 years.
Synapse has enriched 10 related papers. Consider them for comparative context: